Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Buy
63
BDTX Quote, Financials, Valuation and Earnings
Last price:
$3.22
Seasonality move
:
-29.92%
Day range:
$3.05 - $3.26
52-week range:
$1.20 - $6.75
Dividend yield:
0%
P/E ratio:
53.50x
P/S ratio:
--
P/B ratio:
1.29x
Volume:
988.2K
Avg. volume:
1.3M
1-year change:
-46.05%
Market cap:
$182.5M
Revenue:
--
EPS (TTM):
$0.06
Analysts' Opinion
-
Consensus RatingBlack Diamond Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $10.75, Black Diamond Therapeutics has an estimated upside of 234.89% from its current price of $3.21.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $9.00 representing 100% downside risk from its current price of $3.21.
Fair Value
-
According to the consensus of 3 analysts, Black Diamond Therapeutics has 234.89% upside to fair value with a price target of $10.75 per share.
BDTX vs. S&P 500
-
Over the past 5 trading days, Black Diamond Therapeutics has overperformed the S&P 500 by 16.45% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Black Diamond Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Black Diamond Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Black Diamond Therapeutics reported revenues of $70M.
Earnings Growth
-
Black Diamond Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Black Diamond Therapeutics reported earnings per share of $0.98.
Enterprise value:
30.1M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
2.45x
Price / Operating cash flow:
14.74x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
77.9%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | $70M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$88.7M | -$85.1M | -$4M | -$20.2M | $54.5M | |
| EBITDA | -$88.2M | -$84.7M | -$3.7M | -$20.2M | $54.6M | |
| Diluted EPS | -$2.39 | -$1.66 | $0.06 | -$0.35 | $0.98 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $297.3M | $188.3M | $108M | $118.8M | $155.7M | |
| Total Assets | $313.3M | $219.5M | $135.6M | $142.5M | $176.2M | |
| Current Liabilities | $18.7M | $19.5M | $12.8M | $16.9M | $16.8M | |
| Total Liabilities | $32.5M | $46.9M | $37.4M | $38.2M | $34.7M | |
| Total Equity | $280.8M | $172.6M | $98.2M | $104.3M | $141.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$76.5M | -$67.9M | $12.3M | -$21.2M | $53.4M | |
| Cash From Investing | $61.4M | -$22.2M | $39.2M | -$13.7M | $8.5M | |
| Cash From Financing | $75K | $76M | $21.4M | $4.1M | $32K | |
| Free Cash Flow | -$76.7M | -$67.9M | $12.3M | -$21.2M | $53.4M | |
BDTX
Sector
Market Cap
$182.5M
$34.4M
Price % of 52-Week High
47.56%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-46.05%
-37.36%
Beta (5-Year)
2.711
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$2.86
200-day SMA
Buy
Level
$2.38
Bollinger Bands (100)
Buy
Level
1.55 - 2.45
Chaikin Money Flow
Sell
Level
-172.9M
20-day SMA
Buy
Level
$2.62
Relative Strength Index (RSI14)
Buy
Level
77.09
ADX Line
Buy
Level
40.14
Williams %R
Sell
Level
-10.3093
50-day SMA
Buy
Level
$2.33
MACD (12, 26)
Buy
Level
0.20
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Neutral
Level
121M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
Stock Forecast FAQ
In the current month, BDTX has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BDTX average analyst price target in the past 3 months is $10.75.
-
Where Will Black Diamond Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Black Diamond Therapeutics share price will rise to $10.75 per share over the next 12 months.
-
What Do Analysts Say About Black Diamond Therapeutics?
Analysts are divided on their view about Black Diamond Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Black Diamond Therapeutics is a Sell and believe this share price will drop from its current level to $9.00.
-
What Is Black Diamond Therapeutics's Price Target?
The price target for Black Diamond Therapeutics over the next 1-year time period is forecast to be $10.75 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BDTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Black Diamond Therapeutics is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BDTX?
You can purchase shares of Black Diamond Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Black Diamond Therapeutics shares.
-
What Is The Black Diamond Therapeutics Share Price Today?
Black Diamond Therapeutics was last trading at $3.22 per share. This represents the most recent stock quote for Black Diamond Therapeutics. Yesterday, Black Diamond Therapeutics closed at $3.21 per share.
-
How To Buy Black Diamond Therapeutics Stock Online?
In order to purchase Black Diamond Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 18
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is up 19.81% over the past day.
Sell
41
NEGG alert for Jul 18
Newegg Commerce [NEGG] is up 17.85% over the past day.
